Search clinical trials for: Anlotinib Hydrochloride Capsules

Total 11114 results

Pfizer

Completed

ARCHER 1009 : A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer (ARCHER 1009)

Non-Small Cell Lung Cancer

United States, Korea, Republic of, United Kingdom, Greece, Slovakia, France, Belgium, Ireland, Japan, Spain, China, Sweden, India, Hungary, Switzerland, Russian Federation, Germany, Mexico, Denmark, Austria, Finland, Poland, South Africa
PharmaMar

Completed

Trial of PM02734 Administered in Combination With Erlotinib in Patients With Advanced Malignant Solid Tumors

Advanced Malignant Solid Tumors

Spain, United States
Garvan Institute of Medical Research

Completed

Alkaline Diet for Insulin Sensitivity (ADIS)

Type 2 Diabetes Mellitus | Dysglycemia

Australia
SCRI Development Innovations, LLC
Bayer

Completed

Sorafenib/Erlotinib Versus Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer

United States
SCRI Development Innovations, LLC
Novartis

Completed

Trial of Erlotinib and BKM120 in Patients With Advanced Non Small Cell Lung Cancer Previously Sensitive to Erlotinib

Non Small Cell Lung Cancer

United States
European Organisation for Research and Treatment...

Completed

Erlotinib Compared With Temozolomide or Carmustine in Treating Patients With Recurrent Glioblastoma Multiforme

Brain and Central Nervous System Tumors

France, Italy, Belgium, Netherlands, United Kingdom
National Cancer Institute (NCI)

Completed

Erlotinib and Sorafenib in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme

Adult Giant Cell Glioblastoma | Adult Glioblastoma | Adult Gliosarcoma | Recurrent Adult Brain Tumor

United States
Jonsson Comprehensive Cancer Center
Aventis Pharmaceuticals; Genentec

Completed

Docetaxel and Erlotinib in Treating Older Patients With Prostate Cancer

Prostate Cancer

United States
Children's Cancer and Leukaemia Group

Unknown

Erlotinib Alone or in Combination With Radiation Therapy in Treating Young Patients With Refractory or Relapsed Malignant Brain Tumors or Newly Diagnosed Brain Stem Glioma

Brain and Central Nervous System Tumors

United Kingdom, Ireland
OSI Pharmaceuticals
National Cancer Institute (NCI)

Completed

Erlotinib Combined With Gemcitabine in Treating Patients With Newly Diagnosed Locally Advanced or Metastatic Pancreatic Cancer or Other Solid Tumors

Pancreatic Cancer | Unspecified Adult Solid Tumor, Protocol Specific

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Erlotinib and Gemcitabine in Treating Patients With Metastatic Breast Cancer Previously Treated With An Anthracycline and/or a Taxane

Breast Cancer

United States
Henan Cancer Hospital

Not yet recruiting

TQB2450 (PD-L1 Inhibitor) Plus Anlotinib Combined With Chemotherapy in the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma

Gastric Cancer | Adenocarcinoma of Esophagogastric Junction
National Cancer Institute (NCI)

Completed

Erlotinib, Gemcitabine, and Radiation Therapy in Treating Patients With Locally Advanced Unresectable Pancreatic Cancer

Adenocarcinoma of the Pancreas | Recurrent Pancreatic Cancer | Stage III Pancreatic Cancer | Stage II Pancreatic Cancer

United States
OHSU Knight Cancer Institute
National Cancer Institute (NCI)

Withdrawn

Phase I/II Study of Postoperative Adjuvant Chemoradiation for Advanced-Stage Cutaneous Squamous Cell Carcinoma of the Head and Neck (cSCCHN)

Squamous Cell Carcinoma of the Skin | Recurrent Skin Cancer | Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity | Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity | Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity | Stage IVA Squamous Cell Carcinoma of the...

United States
National Cancer Institute (NCI)

Completed

Erlotinib and Radiation Therapy With or Without Cisplatin in Treating Patients With Mouth or Throat Cancer

Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity | Stage II Squamous Cell Carcinoma of the Oropharynx | Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity | Stage III Squamous Cell Carcinoma of the Oropharynx | Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity and other conditions

United States
Heather Wakelee
Novartis; Genentech, Inc.

Terminated

Phase 1 Erlotinib and Dovitinib (TKI258) in Advanced Non-small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer (NSCLC), Recurrent | Non-small Cell Lung Cancer (NSCLC), Stage IV

United States
Akeso
Akeso Tiancheng, Inc

Completed

A Study of Penpulimab Combination Therapy in Patients With Advanced Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Eisai Inc.

Completed

Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer

United States, Hong Kong, Taiwan, Korea, Republic of, Singapore, Thailand, Malaysia
National Cancer Center, Korea
Hoffmann-La Roche

Active, not recruiting

Neoadjuvant Erlotinib for Operable Stage II or IIIA NSCLC With EGFR Mutations

NSCLC Stage II | NSCLC, Stage IIIA

Korea, Republic of
David M. Jackman, MD
Beth Israel Deaconess Medical Center; Genentech, Inc.; Brigham and Women's Hospital

Completed

Erlotinib Therapy and Subsequent Development of Mechanisms of Secondary Resistance in Patients With NSCLC

Non-small Cell Lung Cancer

United States
Pfizer

Completed

A Randomized Trial Of PF-00299804 Taken Orally Versus Erlotinib Taken Orally For Treatment Of Advanced Non-Small Cell Lung Cancer That Has Progressed After One Or Two Prior Chemotherapy Regimen

Non-small Cell Lung Cancer

United States, Taiwan, Korea, Republic of, Australia, Brazil, Spain, United Kingdom, Singapore, Canada, Hong Kong, Poland, Puerto Rico
Hoffmann-La Roche

Completed

A Study of Tarceva (Erlotinib) to Compare Two Different Doses in in Currently Smoking Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (CURRENTS)

Non-Small Cell Lung Cancer

Spain, France, Germany, Switzerland, China, Turkey, Denmark, Egypt, Netherlands
University of Alabama at Birmingham
Genentech, Inc.; OSI Pharmaceuticals

Completed

UAB 0718 - Phase II Trial to Assess Target Oral Therapy as Adjuvant Chemoprevention in High-Risk Head and Neck Cancer (UAB0718)

Head and Neck Cancer

United States
The First Affiliated Hospital of Guangzhou Medical...

Unknown

Erlotinib 100mg or 150mg in Treating EGFR Mutated NSCLC

NSCLC | EGFR Mutation

China
University Hospital, Strasbourg, France

Unknown

Clinical Investigation of Erlotinib as an HCV Entry Inhibitor

Chronic Hepatitis C Infection | HCV Genotype 1b

France
Samsung Medical Center

Unknown

The Continuation of Erlotinib

Non-small Cell Lung Cancer

Korea, Republic of
Henry Ford Health System
Genentech, Inc.

Terminated

Erlotinib (Tarceva) During First Line Standard Platinum Containing Chemo for Advanced Squamous Cell Head and Neck Cancer

Head and Neck Cancer | Carcinoma, Squamous Cell
University of Cincinnati
Genentech, Inc.

Withdrawn

The Role of Erlotinib an Epidermal Growth Factor Receptor (EGFR) Inhibitor in the Treatment of Myelodysplastic Syndrome

Myelodysplastic Syndrome

United States
Dana-Farber Cancer Institute
Astellas Pharma Inc

Terminated

Rapid Plasma Genotyping For Early Initiation Of Erlotinib In EGFR Mutant Lung Cancer

Non-Small Cell Lung Cancer | Epidermal Growth Factor Receptor

United States
Eli Lilly and Company

Completed

A Study of Emibetuzumab in Non Small Cell Lung Cancer (NSCLC) Participants (Chime)

Carcinoma, Non-Small-Cell Lung

United States, Germany, Spain, Belgium, France, United Kingdom, Netherlands, Italy, Israel, Korea, Republic of
Dartmouth-Hitchcock Medical Center
Sanofi; Genentech, Inc.

Completed

Erlotinib or Placebo Following Chemoradiotherapy (Chemo/RT) in Stage III Non-Small Cell Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung | NSCLC | Non-small Cell Lung Cancer

United States
Massachusetts General Hospital
Dana-Farber Cancer Institute; Genentech, Inc.

Completed

Erlotinib in Patients With Resected, Early Stage NSCLC With Confirmed Mutations in the EGFR

Non-small Cell Lung Cancer

United States
Hoffmann-La Roche

Completed

A Study of Erlotinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations

Non-Squamous Non-Small Cell Lung Cancer

Portugal
Oncology Specialists, S.C.

Completed

Single Agent Erlotinib in Chemotherapy-naive Androgen Independent Prostate Cancer

Prostate Cancer

United States
Groupe Francophone des Myelodysplasies
Roche Pharma AG

Completed

Erlotinib in Higher Risk Myelodysplastic Syndrome

Myelodysplastic Syndrome

France
Hoffmann-La Roche

Completed

A Study of Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small Cell Lung Cancer Carrying an Activating Epidermal Growth Factor Receptor (EGFR) Mutation

Non-Squamous Non-Small Cell Lung Cancer

Spain, Taiwan, Japan, United States, France, Germany, Korea, Republic of, Malaysia
University of Utah

Completed

A Phase 2 Study of Tarceva for Untreated, Good Prognosis Patients With Advanced Non-Small Cell Lung Cancer

Lung Cancer

United States
Wu Jieping Medical Foundation
Zhejiang Cancer Hospital; Fudan University; Shanghai Chest Hospital; Shanghai Pulmonary... and other collaborators

Unknown

The Value of Radiotherapy in the Oligometastatic Non-squamous Non-small Cell Lung Cancer With Clinical Benefits From Erlotinib as Second-line Treatment (ROLE)

Non Small Cell Lung Cancer, Oligometastatic

China
Ontario Clinical Oncology Group (OCOG)
Roche Pharma AG

Completed

Phase II Trial of Erlotinib and Concurrent Palliative Thoracic Radiation Therapy for Non-small Cell Lung Cancer (PEARL)

Non-small Cell Lung Cancer

Canada
Zhejiang Cancer Hospital

Unknown

Erlotinib Combined With Radiotherapy in Patients With Non-resectable Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC) (RT0901)

Non-small Cell Lung Cancer

China
Amsterdam UMC, location VUmc

Completed

Safety Study of Radiotherapy and Concurrent Erlotinib (Tarceva®) for Brain Metastases From a Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer | Brain Metastases

Netherlands
Guangdong Provincial People's Hospital

Unknown

Efficacy of Erlotinib for Brain Metastasis of Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer | Brain Metastases
Hospital of Navarra
Dr. Enrique Martínez López

Unknown

Study of 3D Radiotherapy With or Without Erlotinib (Tarceva®) in Patients With Localized Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

Spain
University of California, Davis
National Cancer Institute (NCI); Genentech, Inc.; Aventis Pharmaceuticals

Completed

Docetaxel and Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors

Lung Cancer | Unspecified Adult Solid Tumor, Protocol Specific

United States
Fred Hutchinson Cancer Center

Completed

Erlotinib, Docetaxel, and Carboplatin in Treating Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cavity Cancer

United States
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center; Northwestern University; Dana-Farber Cancer Institute and other collaborators

Completed

Ph II OSI-774 (Erlotinib,Tarceva) In Advanced Bronchioloalveolar Cell Lung Cancer

Bronchioloalveolar Cell Variant of Non-small Cell Lung Cancer

United States
Oslo University Hospital

Terminated

Thoracal Radiotherapy and Tarceva (ThoRaT)

Cancer

Norway
Hoffmann-La Roche

Completed

A Study of Erlotinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (ESSENCE)

Non-Small Cell Lung Cancer

Serbia
Hoffmann-La Roche

Completed

A Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib Treatment

Non-Small-Cell Lung Carcinoma

United States, Spain, France, Italy, Belgium, Korea, Republic of, Taiwan, United Kingdom, Luxembourg, Australia, Netherlands, Germany, Singapore, Denmark, Russian Federation, Sweden
Kyowa Kirin Co., Ltd.

Completed

A Study of ARQ 197 in Combination With Erlotinib

Non-small-cell Lung Cancer

Japan

Search clinical trials for: Anlotinib Hydrochloride Capsules

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uruguay

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations